At present, cancer antigen 125 (CA125) is the most investigated early detection marker for ovarian cancer and, because the protein detection in circulation has limited sensitivity, tumor-associated auto-antibodies may improve on the performance of CA125 alone. This evidence concerns the gene MUC16 and neoplasm.